Neuland Laboratories Limited (NEULANDLAB.NS)
NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹19,350.00 (+1.55%) as of
Key statistics
- Market cap
- 248.26B
- P/E (TTM)
- 49.87
- Forward P/E
- 39.87
- EPS (TTM)
- 387.98
- Dividend yield
- 0.18%
- 52-week range
- 11,500.00 – 24,225.00
- Beta
- 0.28
- Revenue (TTM)
- 23.72B
- Profit margin
- 20.99%
- Analyst target
- ₹24,678.50
- Volume
- 14.91k
About Neuland Laboratories Limited
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Hyderabad, India
- Employees
- 2,183
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.